Charles River climbs after lifting annual profit forecast

Charles River Laboratories International

05/08/2026 13:02

** Shares of contract drug developer Charles River Laboratories CRL.N rise 8.8% to $254.73 premarket
** Co expects annual adj. per share profit between $11.15 and $11.45, up from its prior view of $10.80 to $11.30
** CRL reports Q2 adj. profit of $3.02/shr vs analysts' average estimate of $2.74/shr, according to LSEG data
** Co's Q2 revenue of $1 billion beats analysts' average expectation of $975.7 million on improving biotech demand
** Up to last close, stock was up 17.4% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))